Page last updated: 2024-10-15

2-amino-4-hydroxy-6,7-dimethyl-5,6,7,8-tetrahydropteridine

Description

2-amino-4-hydroxy-6,7-dimethyl-5,6,7,8-tetrahydropteridine: used as a synthetic cofactor in place of tetrahydrofolate; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135406872
CHEBI ID188218
SCHEMBL ID156195
MeSH IDM0046366

Synonyms (17)

Synonym
611-54-1
nsc146788
nsc-146788
dmph4
2-amino-4-hydroxy-6,7-dimethyl-5,6,7,8-tetrahydropteridine
6,7-dimethyltetrahydropterin
2-amino-6,7-dimethyl-5,6,7,8-tetrahydro-3h-pteridin-4-one
CHEBI:188218
6,7-dimethyl-5,6,7,8-tetrahydropterin
nsc 146788
4(1h)-pteridinone, 2-amino-5,6,7,8-tetrahydro-6,7-dimethyl-
SCHEMBL156195
ARHXUJTYUBUXBB-UHFFFAOYSA-N
2-amino-6,7-dimethyl-5,6,7,8-tetrahydro-4-pteridinol
2-imino-6,7-dimethyl-1,2,5,6,7,8-hexahydropteridin-4-ol
DTXSID50976620
PD050543

Dosage Studied

ExcerptReference
" The inhibitory effect of the high dosages of OE(2) correlated with an increase in the apparent K(m) values (decreased affinity) for both substrate and cofactor, and a decrease in the V(max) compared with the lower dosage groups."( Effects of ovariectomy and oestradiol-17beta replacement on brain tyrosine hydroxylase in the catfish Heteropneustes fossilis: changes in in vivo activity and kinetic parameters.
Chaube, R; Joy, KP, 2002
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pterins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (55.00)18.7374
1990's5 (25.00)18.2507
2000's4 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]